Wesley Burkett, MD, discusses the next steps for treating patients with endometrial cancer.
Wesley Burkett, MD, a fellow in gynecologic oncology at the University of North Carolina School of Medicine, discusses the next steps for treating patients with endometrial cancer.
The current standard of care options for treating this patient population are to use Immune and targeted therapies. However, options remain limited, leaving a need for more strategies to be evaluated and developed.
On top of this, Burkett emphasizes the need to address the disparities that exist in this space as patients' outcomes are directly impacted.
Transcription:
0:08 | I think we have been able to have more bio directed treatments for endometrial cancer. Of course, there are other issues with endometrial cancer that definitely have to be addressed. That includes some disparities in treatment outcomes or cancer outcomes in endometrial cancer.
0:30 | I think that is something that we definitely need to address and we should have. It needs to be addressed yesterday. [We are] working forward and trying to minimize and make sure we are providing appropriate and equitable care to everyone and figuring out ways that we can help to narrow that gap.
Birrer Assesses Tolerability Factors in Use of Lenvatinib/Pembrolizumab for Endometrial Cancer
June 11th 2024During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion focusing on dosing and tolerability issues in treating patients with advanced endometrial cancer with lenvatinib plus pembrolizumab.
Read More